WCLC 2025: Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds
A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a…
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a…
Ahmed Elbediwy, Kingston University, and Nadine Wehida, Kingston University For years, health authorities have warned…
Prostate cancer is one of the leading causes of cancer-related death in men. Most patients…
Many modern cancer treatments are highly effective at reducing or eliminating tumours, but they can…
People with type 2 obesity-driven diabetes tend to have more aggressive breast cancers, but no…
The Terasaki Institute for Biomedical Innovation announces a significant advancement in addressing cancer-associated cachexia (CAC),…
The mitochondria may be the powerhouse of the cell, but mounting evidence suggests this organelle…
New research led by investigators at Mass General Brigham, USA, suggests a link between a…
A natural compound could help fight aggressive leukaemia and amplify the effect of chemotherapy drugs.…
In a preclinical study, researchers found that tamoxifen encourages uterine cell growth; the findings could…